Kallikrein 5/KLK5 Protein, Mouse, Recombinant (His)

The inhibition of kallikrein 5 (KLK5) has been identified as a potential strategy for treatment of the genetic skin disorder Netherton syndrome, in which loss-of-function mutations in the SPINK5 gene lead to down-regulation of the endogenous inhibitor LEKTI-1 and profound skin-barrier defects with severe allergic manifestations. To aid in the development of a medicine for this target, an X-ray crystallographic system was developed to facilitate fragment-guided chemistry and knowledge-based drug-discovery approaches.

Pack Size	Availability	Price/USD
100 μg	5 days	$ 418.00
500 μg	5 days	$ 1,670.00
1 mg	5 days	$ 2,800.00

Pack Size

Availability

Price/USD

Quantity

100 μg

5 days

$ 418.00

500 μg

5 days

$ 1,670.00

1 mg

5 days

$ 2,800.00

Description

Species	Mouse
Expression System	HEK293
Tag	C-His
Accession Number	Q9D140
Synonyms	SCTE, KLKL2, KLK5, KLK-L2, Klnc, Kallikrein c
Construction	Recombinant Mouse Kallikrein 5/KLK5 Protein is expressed from HEK293 with His tag at the C-Terminus. It contains Gly30-Asn293.[Accession \|Q9D140]
Protein Purity	> 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC
Molecular Weight	The protein has a predicted MW of 29.9 kDa. Due to glycosylation, the protein migrates to 40-50 kDa based on Tris-Bis PAGE result.

Endotoxin	Less than 1EU per μg by the LAL method.
Formulation	Lyophilized from 0.22μm filtered solution in 20mM NaAc, 150mM NaCl (pH 5.0). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution	Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in 20mM NaAc, 150mM NaCl (pH 5.0).
Stability & Storage	-20 to -80°C for 12 months as supplied from date of receipt. -20 to -80°C for 3-6 months in unopened state after reconstitution. 2-8°C for 2-7 days after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Shipping	In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
Research Background	The inhibition of kallikrein 5 (KLK5) has been identified as a potential strategy for treatment of the genetic skin disorder Netherton syndrome, in which loss-of-function mutations in the SPINK5 gene lead to down-regulation of the endogenous inhibitor LEKTI-1 and profound skin-barrier defects with severe allergic manifestations. To aid in the development of a medicine for this target, an X-ray crystallographic system was developed to facilitate fragment-guided chemistry and knowledge-based drug-discovery approaches.